IgA Nephropathy Secondary to Ipilimumab Use

Ipilimumab is a human monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 approved for the treatment of non-small-cell lung cancer (NSCLC) and other malignancies. Despite a high prevalence of other immune-related adverse events (irAEs), checkpoint inhibitor (CPI)-related nephro...

Descripción completa

Detalles Bibliográficos
Autores principales: Dougherty, Sean C., Desai, Nisa, Cathro, Helen P., Renaghan, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647129/
https://www.ncbi.nlm.nih.gov/pubmed/34950709
http://dx.doi.org/10.1159/000519169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647129/
https://www.ncbi.nlm.nih.gov/pubmed/34950709
http://dx.doi.org/10.1159/000519169

Ejemplares similares